Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase EARLY_PHASE1 1

Status

Withdrawn 1Unknown 1Terminated 1Completed 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4Gynecologic 1

Conditions

Breast Neoplasms 4Urogenital Neoplasms 1Prostatic Neoplasms 1Prostatic Diseases 1Ovarian Neoplasms 1Neoplasms by Site 1Neoplasms 1Neoplasm Metastasis 1Genital Neoplasms, Male 1Genital Diseases, Male 1Endometrial Neoplasms 1

Interventions

Trastuzumab 597Paclitaxel 562Cyclophosphamide 545Docetaxel 479Capecitabine 387Letrozole 350Fulvestrant 311Doxorubicin 285Carboplatin 277Tamoxifen 257Anastrozole 219exemestane 211Epirubicin 210Radiotherapy 197Bevacizumab 189pertuzumab 177Gemcitabine 163Vinorelbine 162pembrolizumab 161Lapatinib 161palbociclib 152Exercise 132Fluorouracil 118Albumin-Bound Paclitaxel 116eribulin 108Magnetic Resonance Spectroscopy 108130-nm albumin-bound paclitaxel 107Everolimus 103Taxes 96Cisplatin 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Breast Neoplasms × onapristone × Clear all
NCT05618613 2025-05-09

ELONA

Context Therapeutics Inc.

Phase 1/2 Terminated
4 enrolled
Breast

Breast Neoplasms

NCT06938711 2025-04-22

A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer

Context Therapeutics Inc.

Phase 1/2 Withdrawn
Breast

Breast Neoplasms

NCT04142892 2022-04-01

ONAWA

SOLTI Breast Cancer Research Group

Phase EARLY_PHASE1 Completed
10 enrolled
Breast

Breast Neoplasms

NCT02052128 2015-06-24

Phase 1-2 Study of Onapristone in Patients With Progesterone Receptor Expressing Cancers

Arno Therapeutics

Phase 1/2 Unknown
60 enrolled
BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡